Sugi Predict

Sugi Predict / Targets / ENTPD1

ENTPD1

Ectonucleoside triphosphate diphosphohydrolase 1 · P49961 · ENTPD1 on Sugi Atlas →

2,711 patent compounds predicted against ENTPD1, 1,846 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3026735 SCHEMBL3026735 0.76 4/20
SCHEMBL791021 SCHEMBL791021 0.72 4/20
SCHEMBL6045168 SCHEMBL6045168 0.69 4/20
SCHEMBL6045179 SCHEMBL6045179 0.69 4/20
SCHEMBL4651055 SCHEMBL4651055 0.68 4/20
SCHEMBL791020 SCHEMBL791020 0.93 3/20
SCHEMBL1062562 SCHEMBL1062562 0.76 3/20
SCHEMBL636535 SCHEMBL636535 0.75 3/20
SCHEMBL636536 SCHEMBL636536 0.75 3/20
SCHEMBL9752397 SCHEMBL9752397 0.74 3/20
SCHEMBL9752399 SCHEMBL9752399 0.74 3/20
SCHEMBL374912 SCHEMBL374912 0.73 3/20
SCHEMBL374913 SCHEMBL374913 0.73 3/20
SCHEMBL4314233 SCHEMBL4314233 0.72 3/20
SCHEMBL6827710 SCHEMBL6827710 0.70 3/20
SCHEMBL791509 SCHEMBL791509 0.69 3/20
SCHEMBL6825637 SCHEMBL6825637 0.69 3/20
SCHEMBL6827694 SCHEMBL6827694 0.68 3/20
SCHEMBL6825639 SCHEMBL6825639 0.68 3/20
SCHEMBL3021626 SCHEMBL3021626 0.67 3/20

Clinical trials — most relevant to ENTPD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation PHASE3UNKNOWN
A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers PHASE2/PHASE3UNKNOWN
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) PHASE1/PHASE2RECRUITING
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma PHASE2RECRUITING
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma PHASE2RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer PHASE2RECRUITING
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 PHASE2NOT_YET_RECRUITING
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors PHASE1/PHASE2NOT_YET_RECRUITING
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector PHASE1/PHASE2RECRUITING
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene PHASE2COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1WITHDRAWN
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer PHASE1COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients EARLY_PHASE1RECRUITING
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 EARLY_PHASE1RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors nanWITHDRAWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Genetics of Middle Ear Disease nanCOMPLETED
Soluble Programmed Death 1 (sPD1) is a Diagnostic Biomarker of ILD in Patients With Rheumatoid Arthritis Disease nanUNKNOWN
Pathophysiology of Paget's Disease of Bone nanCOMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases nanNOT_YET_RECRUITING
Poor Sleep and Inflammation in HIV-Infected Adults nanCOMPLETED
Hereditary Parkinson s Disease Natural History Protocol nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ENTPD1 binder may also engage these)

ProteinNameSimilarity
Q9MYU4 — 0.989 Q9MYU4 →
P97687 — 0.989 P97687 →
O18956 — 0.987 O18956 →
P55772 — 0.987 P55772 →
O93295 — 0.986 O93295 →
ENTPD5 Nucleoside diphosphate phosphatase ENTPD5 0.978 landscape →
E1BPW0 — 0.976 E1BPW0 →
D2GZV9 — 0.976 D2GZV9 →
Q9WUZ9 — 0.975 Q9WUZ9 →
E1C1L6 — 0.974 E1C1L6 →
Q6P6S9 — 0.973 Q6P6S9 →
Q9DBT4 — 0.973 Q9DBT4 →
Q28CF8 — 0.972 Q28CF8 →
ENTPD3 Ectonucleoside triphosphate diphosphohydrolase 3 0.970 landscape →
Q9QYC8 — 0.967 Q9QYC8 →
P79784 — 0.967 P79784 →
Q9Y227 — 0.966 Q9Y227 →
O35795 — 0.966 O35795 →
Q3U0P5 — 0.966 Q3U0P5 →
Q8K0L2 — 0.965 Q8K0L2 →
Q9ER31 — 0.964 Q9ER31 →
O75354 — 0.964 O75354 →
Q5REF6 — 0.962 Q5REF6 →
Q62469 — 0.961 Q62469 →
Q5DRK1 — 0.961 Q5DRK1 →
Q9NQZ7 — 0.960 Q9NQZ7 →
Q3TCT4 — 0.959 Q3TCT4 →
O55026 — 0.959 O55026 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.958 landscape →
Q71RP1 — 0.957 Q71RP1 →